AmpliPhi Biosciences has raised $44 m in total funding

AmpliPhi Biosciences Net income (Q1, 2020)-5.1 M

AmpliPhi Biosciences Cash, 31-Mar-202024.2 M

## Founding Date | 1989 |

## AmpliPhi Biosciences total Funding | $44 m |

## AmpliPhi Biosciences latest funding size | $13 m |

## Time since last funding | 6 years ago |

## AmpliPhi Biosciences investors | ROTH Capital Partners, Third Security, RA Capital Management, BioScience Managers Limited |

AmpliPhi Biosciences's latest funding round in March 2015 was reported to be $13 m. In total, AmpliPhi Biosciences has raised $44 m

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Revenue | 409.0k | |||||

| 16% | (45%) | ||||

## R&D expense | 5.8m | 4.0m | 5.7m | 2.9m | 4.9m | 9.8m |

## General and administrative expense | 6.9m | 6.4m | 8.4m | 7.6m | 5.7m | 9.3m |

## Operating expense total | 12.7m | 10.4m | 14.1m | 10.5m | 10.6m | 19.1m |

## EBIT | (14.1m) | (10.2m) | (23.4m) | (16.2m) | (12.5m) | (19.8m) |

| (3450%) | |||||

## Interest expense | ||||||

## Interest income | 6.0k | 96.0k | ||||

## Pre tax profit | (589.0k) | (19.4m) | (14.1m) | (12.4m) | (19.5m) | |

## Income tax expense | (73.0k) | (556.0k) | (1.3m) | (328.0k) | ||

## Net Income | 23.1m | (516.0k) | (18.8m) | (12.8m) | (12.1m) | (19.5m) |

USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 101.0k | 103.0k | 102.0k | ||||||||||||||||

## R&D expense | 1.0m | 1.9m | 1.8m | 972.0k | 1.1m | 728.0k | 2.0m | 1.2m | 1.7m | 1.5m | 1.1m | 1.5m | 1.7m | 361.0k | 1.5m | 3.1m | 3.0m | 2.8m | |

## General and administrative expense | 1.6m | 2.0m | 1.7m | 1.4m | 1.6m | 1.6m | 2.6m | 2.5m | 1.8m | 1.9m | 2.8m | 1.6m | 1.6m | 1.4m | 1.3m | 2.1m | 2.1m | 3.8m | 2.2m |

## Operating expense total | 2.6m | 3.8m | 3.5m | 2.4m | 2.7m | 2.3m | 4.6m | 3.7m | 3.4m | 3.4m | 3.9m | 1.6m | 3.1m | 3.1m | 1.6m | 3.6m | 5.2m | 6.8m | 4.9m |

## EBIT | (2.6m) | (3.7m) | (5.2m) | (2.3m) | (2.6m) | (2.4m) | (4.5m) | (3.6m) | (3.4m) | (3.4m) | (9.7m) | (746.0k) | (3.1m) | (3.1m) | (1.6m) | (3.6m) | (5.2m) | (6.8m) | |

| (3711%) | (5079%) | (2223%) | ||||||||||||||||

## Interest expense | |||||||||||||||||||

## Interest income | 129.0k | 3.0k | 4.0k | 28.0k | 13.0k | 2.0k | |||||||||||||

## Pre tax profit | (7.8m) | (779.0k) | (3.0m) | (1.6m) | (4.2m) | (7.0m) | |||||||||||||

## Income tax expense | (1.3m) | ||||||||||||||||||

## Net Income | (10.1m) | 13.9m | 21.2m | (14.5m) | 10.8m | 5.4m | (3.1m) | (3.9m) | (2.4m) | (3.2m) | (6.5m) | (779.0k) | (3.1m) | (3.0m) | (1.6m) | (3.6m) | (4.2m) | (7.0m) | (5.1m) |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Cash | 6.6m | 9.4m | 5.7m | 5.1m | 8.2m | 6.0m |

## Accounts Receivable | 100.0k | 125.0k | 25.0k | |||

## Prepaid Expenses | 339.0k | 521.0k | 253.0k | 251.0k | 622.0k | |

## Current Assets | 7.0m | 10.0m | 6.4m | 5.4m | 8.4m | 6.7m |

## PP&E | 1.2m | 1.1m | 1.1m | 816.0k | 503.0k | 2.2m |

## Goodwill | 7.6m | 7.6m | 7.6m | 3.5m | ||

## Total Assets | 28.6m | 31.5m | 18.2m | 11.1m | 11.9m | 25.5m |

## Accounts Payable | 1.2m | 1.5m | 1.7m | 578.0k | 729.0k | 547.0k |

## Dividends Payable | 368.0k | 38.0k | ||||

## Short-term debt | 803.0k | 1.3m | ||||

## Current Liabilities | 1.9m | 2.4m | 3.6m | 2.0m | 2.6m | 4.9m |

## Long-term debt | 803.0k | 1.6m | ||||

## Total Debt | 1.6m | 2.9m | ||||

## Total Liabilities | 23.2m | 6.9m | 8.5m | 3.4m | 3.4m | 10.9m |

## Common Stock | 2.0m | 59.0k | 95.0k | 323.0k | 99.0k | |

## Additional Paid-in Capital | 363.5m | 375.2m | 390.9m | 401.8m | 414.5m | 172.0m |

## Retained Earnings | (362.0m) | (362.5m) | (381.4m) | (394.2m) | (406.3m) | (157.5m) |

## Total Equity | 3.4m | 12.7m | 9.7m | 7.7m | 8.5m | 14.6m |

## Debt to Equity Ratio | 0.2 x | |||||

## Debt to Assets Ratio | 0.1 x | |||||

## Financial Leverage | 8.3 x | 2.5 x | 1.9 x | 1.4 x | 1.4 x | 1.7 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Net Income | 23.1m | (516.0k) | (18.8m) | (12.8m) | (12.1m) | (19.5m) |

## Depreciation and Amortization | 158.0k | 330.0k | 369.0k | 374.0k | 389.0k | 1.4m |

## Accounts Receivable | (92.0k) | (25.0k) | 100.0k | |||

## Accounts Payable | (977.0k) | 296.0k | 298.0k | (838.0k) | 343.0k | (1.4m) |

## Cash From Operating Activities | (12.6m) | (9.8m) | (10.6m) | (9.2m) | (9.4m) | (15.6m) |

## Purchases of PP&E | (1.2m) | (210.0k) | (279.0k) | (58.0k) | (44.0k) | (224.0k) |

## Cash From Investing Activities | (1.2m) | (210.0k) | (279.0k) | (58.0k) | (44.0k) | 2.9m |

## Dividends Paid | (80.0k) | |||||

## Cash From Financing Activities | 12.8m | 7.2m | 8.7m | 12.5m | 9.0m | |

## Net Change in Cash | (13.8m) | 2.8m | (3.7m) | (579.0k) | 3.0m | (3.7m) |

USD | Q1, 2014 |
---|---|

## Financial Leverage | -1.4 x |